The Loop Is Closing — and Diabetes Is Showing the Rest of Medtech What That Costs

In New Orleans last weekend, the diabetes-technology field stopped arguing about whose sensor is more accurate and started arguing about something harder: how much of the patient you can remove from the loop entirely.

That was the through-line of the American Diabetes Association’s 86th Scientific Sessions, held June 5–8. Insulet, Dexcom, Medtronic’s MiniMed, Tandem, Beta Bionics, and a clutch of smaller entrants each brought data, but the data all pointed the same direction — toward systems that sense a physiological signal and act on it without a human deciding anything in the moment. Insulet’s STRIVE pivotal trial and EVOLUTION 3 feasibility study were the clearest statement of the thesis: the company’s investigational fully closed-loop system for type 2 diabetes adjusts insulin “with no user settings,” and its EVOLUTION 3 cohort reached 64% time in range from a baseline A1C of 8.1%. MiniMed’s chief product and technology officer told MedTech Dive that, having watched the competition’s results at the meeting, his team is “clearly ahead” in the same race.

The phrase doing the work is fully closed loop — no carb counting, no meal announcements, no dosing math. It is a deliberate step beyond today’s hybrid systems, which still ask the user to tell the device when they’re about to eat. And it is, notably, a product category that does not yet exist commercially. Insulet’s incremental Omnipod 6 — which improved time in range to 77% for type 1 and 76% for type 2 users versus 73% on the current Omnipod 5 — is slated for next year, but its fully closed-loop type 2 system isn’t expected to launch until 2028, with a 510(k) filing planned for 2027. MiniMed is roughly halfway through enrollment in its own pivotal trial. The field is committing capital, trial infrastructure, and public narrative to a category whose proof and reimbursement are still years out.

For readers whose beat isn’t diabetes, that is the part worth sitting with. Diabetes is not a special case here; it is the leading indicator. It arrived at autonomy first because it has the two ingredients that make a closed loop tractable: a single variable you can measure continuously and a single output you can titrate. Once a field has both, the basis of competition migrates predictably — from is the measurement right? to how much of the human can we take out? Any device category approaching sensor maturity is on the same path.

Cardiovascular and neurological device makers are already on it. Earlier this year, Medtronic won FDA approval for BrainSense Adaptive Deep Brain Stimulation, the first closed-loop DBS system, which senses brain signals and adjusts its own therapy without a clinician intervening — and more than 1,000 patients have already received it. A growing body of work in closed-loop autonomic neuromodulation is pushing the same sense-and-respond logic into heart failure and arrhythmia management, building on devices like CVRx’s Barostim. The diabetes field is simply further down a road that cardiology, neurology, and others are now entering.

Which is why the costs diabetes is paying now are the costs those fields should be pricing in. Three travel across every vertical. First, autonomy is a reimbursement and liability problem before it is an engineering problem — the diabetes companies are pre-announcing years ahead of coverage because payers and the FDA have no settled framework for “the device decided.” Second, the hardest moat isn’t the algorithm; it’s trust transfer — persuading a clinician to cede a judgment call they were trained to own. Third, autonomy reshapes the market beyond the original patient. Dexcom’s CONNECT trial, the first Level A evidence for continuous glucose monitoring in type 2 patients not on insulin, posted a 0.9-percentage-point greater A1C reduction than routine care — and in doing so argued that a tool built for the most acute users belongs with a far larger, lower-acuity population. As Fierce Biotech noted, that population is the next battleground.

The open question for the industry is not whether the loop closes. It is whether the evidentiary, regulatory, and trust structures mature fast enough to meet the devices when they arrive. Diabetes is running the experiment in public. Everyone else should be taking notes.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.

RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The week’s signal sits in two places. Diabetes tech dominated the news cycle out of ADA, with three of the major players posting pivotal data or label expansions and a notable tuck-in acquisition. Underneath that, a fresh wave of recalls and warning letters kept landing on quality systems and sterility — not core technology — a reminder that post-market exposure is where well-funded device makers are still getting caught. Capital kept moving regardless; M&A hasn’t cooled.

8 things to watch this week:

1. 🩸 Insulet posts pivotal Omnipod 6 and fully-closed-loop data at ADA

Insulet’s STRIVE pivotal trial showed improved glucose control with the next-gen Omnipod 6 versus Omnipod 5, while its EVOLUTION 3 study of a fully closed-loop system for type 2 diabetes lifted time-in-range to 64% and cut daily insulin from 86 to 58 units with no weight gain. A 2027 FDA filing and 2028 launch are the targets — the fully-closed-loop race is now the category’s real frontier. Drug Delivery Business + 2

Drug Delivery Business News

2. 🌐 Tandem wins expanded CE mark for type 2 and pregnancy use

Tandem’s t:slim X2 and Mobi pumps with Control-IQ+ are now CE-marked in Europe for adults with type 2 diabetes and for type 1 patients during pregnancy, backed by the 2IQP and CIRCUIT trials. Reimbursement and interoperability — not the algorithm — will decide who takes share as the closed-loop category matures. Medical Device Network

Medical Device Network

3. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.

The Commercial Launch & Impact Framework (CLIF) is a fast, external diagnostic that finds where your commercial story breaks — before a buyer or investor does. One week, an independent outside read, decision-grade clarity before you raise, launch, or scale.

See how it works →

Sponsored by RŌG Health

4. 🔬 Dexcom buys Nutrisense as level-A evidence backs CGM for type 2

At ADA, new data delivered the ADA’s highest (level A) evidence for continuous glucose monitors in type 2 non-insulin users, which Dexcom’s CEO expects to reshape the standard of care; the company also acquired metabolic-health firm Nutrisense. The CGM market is pushing decisively beyond insulin-dependent patients. MedTech Dive

MedTech Dive

5. ⚠️ BD recalls ChloraPrep and FREPP skin-prep lots over fungal contamination

BD is recalling lots of ChloraPrep Clear 1 mL and FREPP Clear 1.5 mL applicators over Aspergillus penicillioides contamination that the FDA warns can cause systemic infection, sepsis, and death if introduced during catheter placement. This is BD’s second ChloraPrep fungal recall in roughly a year — a sterility-control problem that isn’t going away. FDA

FDA

6. 🧪 Galmed pivots into GI medtech with $4.5M Colospan acquisition

Galmed signed a $4.5M definitive agreement to acquire Colospan, whose CG-100 intraluminal bypass device holds FDA Breakthrough Device status and a CE mark and is in a U.S. pivotal IDE trial; the device protects anastomotic connections after colorectal surgery and reduces the need for diverting stomas. A small deal, but a clean case study in how Breakthrough-designated devices are getting valued and acquired. Stock TitanMedical Buyer

Pharmaceutical Executive

7. 🏭 Boston Scientific to build $138M, 300-job distribution hub in Indiana

Boston Scientific will invest $138M in a 500,000-square-foot distribution and light-manufacturing facility in Plainfield, Indiana, expected to create up to 300 high-wage jobs, on top of recent investments in Ireland and Minnesota. Domestic logistics depth is becoming a competitive variable for the largest players. MassDevice

MassDevice

8. 🔧 Medline draws an FDA warning letter over cleanroom quality failures

The FDA cited 250 complaints on Medline’s angiographic syringes between June 2023 and February 2026, flagging particulate accumulation on manufacturing equipment and a last documented cleanroom-equipment cleaning dating to November 2023 — after which 114 foreign-matter complaints were logged. A textbook quality-system gap becoming a field problem. MedTech Dive

MedTech Dive

🔎 Bonus: worth a read

Founders face pressure from all sides as biotech crawls toward recovery

A dispatch from Salt Lake City’s Altitude Lab, where biotech founders — first-timers and 20-year veterans alike — talk candidly about raising capital in a risk-averse market that’s chasing AI hype over slow-moving science. A grounded look at the sequencing and storytelling challenges early-stage life science leaders are navigating right now.

BioSpace

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

A Quiet Guidance Document Just Changed What Every Device Submission Has to Answer

The medtech headlines this week belonged to the usual heavyweights — another nine-figure acquisition, another cardiovascular recall working its way through the courts. But the development most likely to touch your next submission didn't come with a press release or a stock-price move. On May 29, the FDA quietly finalized its guidance on the content of human factors information in device marketing submissions, closing out a draft that had been pending since December 2022. It is exactly the kind of document that gets skimmed and filed. It shouldn't be.

Human factors information is the evidence that a device can be used safely by its intended users — that the people operating it won’t make the kind of mistakes that injure patients. For more than a decade the FDA has folded human factors review into 510(k) and PMA evaluations, but it was never fully clear which devices actually needed validation testing in the submission itself. Two manufacturers with similar products could reasonably reach opposite conclusions. The final guidance is the agency’s attempt to end that ambiguity.

It keeps the three-tier structure from the draft. A Category 1 submission, for modified devices only, needs just a high-level summary. Category 2 needs a rationale for why the device has no critical tasks — the steps where a use error would cause harm. Category 3 requires a full human factors validation study. What’s new is a fourth checkpoint in the agency’s decision flowchart, Decision Point D, which sits after a manufacturer has already identified critical tasks and asks whether validation data actually needs to go in the submission. The answer turns on three things: the device’s history of safe use, the complexity of its user interface, and whether existing risk controls are already adequate.

On its face, Decision Point D reads like relief. Under the 2022 draft, identifying a critical task pushed you straight into a mandatory validation study. The new checkpoint creates room to argue that one isn’t necessary — that a long record of safe use for the same intended users in the same environment is justification enough. Human factors consultants have read it that way, framing the change as the agency’s growing flexibility about how use-safety gets demonstrated, with risk analysis rather than reflexive testing at the center.

The lawyers see the catch. In its analysis, Hyman, Phelps & McNamara flagged a footnote tying Decision Point D to the Quality Management System Regulation, along with a pointed recommendation that manufacturers keep human factors information on hand whether or not they submit it. The implication is that data you successfully argue out of your premarket file doesn’t disappear — it becomes something an investigator can ask for during a QMSR inspection. The work doesn’t go away. It moves from a room where you control the timing to one where the FDA does. And the firm’s experience is that review teams expect to see study results regardless, often through a request for additional information mid-review.

There’s a second change with quieter reach. The FDA updated its eSTAR templates — the structured forms nearly every submission now flows through — to require selecting a human factors category. That makes human factors a checkbox on every device application, not just the ones where it was once obviously relevant. A decision that used to be implicit is now mandatory, in writing, every time.

This is where the structural weight lands, and it doesn’t land evenly. A large manufacturer with a dedicated human factors team and a mature quality system absorbs this as a process tweak. The mid-tier innovator — a strong product, a regulatory function built for legacy 510(k) work — is the one now expected to defend a category selection, maintain inspection-ready files it may never submit, and navigate an interpretation the agency and its own consultants don’t fully agree on. That gap in readiness is itself a competitive variable.

The clock is already running. The FDA built in a roughly 60-day operationalization window and generally doesn’t expect compliant submissions before August 1, though it will review the new information sooner if offered. That leaves a narrow runway to map current pipelines against the new flowchart and decide, device by device, what to test and what to defend.

The deals and the recalls will get the clicks this week. But it’s the document nobody reads aloud that quietly rewrites what every team in the industry has to prove.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The week’s signal was risk and capital moving at once. Quality problems surfaced inside two of the industry’s biggest franchises while the consolidation engine kept running — Olympus, Boston Scientific, and DePuy Synthes all put money to work — and the FDA’s looser posture on wellness claims opened the floodgates on consumer blood-pressure features. All eyes now turn to Wednesday, when Medtronic closes out the sector’s earnings season..

8 things to watch this week:

1. 📊 Medtronic shares slide into Wednesday’s fiscal Q4 report

Medtronic fell roughly 6% in the holiday-shortened week, closing at $73.81 after four straight down sessions, ahead of fiscal Q4 and full-year results due before the open on June 3. The print caps the sector’s earnings season and follows the company’s $650M deal for SPR Therapeutics — a read on whether its growth-by-acquisition strategy is convincing investors.

TS2

2. 🫀 Boston Scientific funnels $1.5B into MiRus with an option to buy its TAVR system

Boston Scientific took a 34% stake in MiRus and secured an exclusive option to acquire its Siegel balloon-expandable TAVR platform for an additional $3 billion. The structured, optioned deal is a notable template — a route back into structural heart after exiting Acurate, without taking on full development risk up front.

Fierce Biotech

3. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored by RŌG Health

4. 💍 Blood-pressure wearables flood the market after the FDA relaxes oversight

After January guidance let companies ship sensors that “estimate, infer, or output” blood pressure for wellness purposes without authorization, Ōura debuted its Ring 5 with blood-pressure signals — and it’s far from alone. The episode marks a real line companies now have to draw between an unregulated wellness claim and a regulated medical one, and some experts are uneasy about it.

The Boston Globe / STAT

5. 🤖 Cornerstone Robotics wins CE mark for its Sentire surgical robot

The Hong Kong-based company secured EU approval for its AI-powered Sentire endoscopic platform across general surgery, gynecology, thoracic, and urology — its formal entry into Europe, following a $200M raise and early UK clinical work with Portsmouth Hospitals. Early users have noted similarities to Intuitive’s da Vinci, a sign the field’s challengers are converging on a familiar interface to ease adoption.

MassDevice

6. ⚠️ J&J’s Abiomed recalls Impella heart pumps after a patient death

J&J initiated a voluntary recall of seven Impella CP sets that don’t meet design specifications, an issue linked to one death and flagged through the company’s retrospective quality audits. It’s the latest in a long string of Impella actions, and J&J was careful to note the issue appeared in 0.01% of global cases — but the cadence keeps post-Abiomed integration risk in the spotlight.

Cardiovascular Business

7. 💉 Beta Bionics earmarks Q2 2027 for its Mint patch pump launch

Beta Bionics set a Q2 2027 commercialization target for Mint, a patch pump pairing its adaptive dosing algorithm with a 200-unit reservoir, three-day wear, and a two-piece reusable/disposable design — pending FDA clearance as an ACE pump. The tubeless category is getting more crowded just as incumbent Insulet manages quality scrutiny of its own.

Drug Delivery Business News

8. 🔓 Dexcom warns of stolen G7 sensors being resold to the public

Dexcom identified two lots of G7 sensors that were marked as scrap, sent for destruction, then stolen and sold to consumers through an unauthorized distributor. One lot carries a sterilization-related infection risk and the other an elevated failure rate — a supply-chain integrity problem that puts a spotlight on vendors’ end-of-life destruction protocols.

MobiHealthNews

🔎 Bonus: worth a read

Founders face pressure from all sides as biotech crawls toward recovery

A dispatch from Salt Lake City’s Altitude Lab, where biotech founders — first-timers and 20-year veterans alike — talk candidly about raising capital in a risk-averse market that’s chasing AI hype over slow-moving science. A grounded look at the sequencing and storytelling challenges early-stage life science leaders are navigating right now.

BioSpace

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

One FDA Approval, Four Advantages at Once: What Guardant's New Liquid Biopsy Signals for Diagnostics.

While the medtech industry’s attention this month has been on robotics launches, the IVL share fight, and a thinning FDA, a quieter milestone landed on May 20: the FDA approved a new version of Guardant Health’s Guardant360 Liquid CDx, and the stock jumped roughly 25% the same week. For a company whose core product is a blood test, a quarter of its market value moved on a label change. The market saw something structural.

Here is what the label actually says. The new assay reads a genomic footprint 100 times wider than the test it replaces — Guardant calls it the largest FDA-approved liquid biopsy panel. The seven companion diagnostic indications already cleared for the prior Guardant360 CDx carry over to the new test without re-filing. Results come back in as little as seven days. And it ships covered: Guardant says Medicare and commercial payers representing more than 300 million lives already reimburse it.

But the number that moved the stock isn’t the gene count. Guardant360 Liquid CDx is, by the company’s account, the first FDA-approved liquid biopsy to combine genomic and epigenomic profiling from a single blood draw — reading not just which mutations a tumor carries, but how its genes are switched on and off. Guardant reports a several-fold jump in sensitivity for detecting circulating tumor DNA over the prior test, and says the paired signal flags clinically actionable findings that sequencing alone would miss. Independent trade coverage of the approval described it in the same terms.

Set that against the competition. Roche’s FoundationOne Liquid CDx, the incumbent, analyzes more than 300 genes and has built its position on panel breadth and companion-diagnostic depth; Tempus won FDA clearance for its xT CDx on a similarly expansive panel. For most of the last five years, the blood-based profiling fight has been an arms race over how many genes a test could read from a tube of blood. Guardant just reframed the contest. The pitch is no longer “more genes” but “more kinds of data” — genotype plus a phenotype-adjacent layer the others don’t report. Whether epigenomic integration proves clinically decisive across tumor types is unproven, and Guardant’s broader phenotype reporting is offered as a professional service the company notes the FDA has not reviewed. What is no longer theoretical is that a regulator has now cleared an assay built on the multiomic premise.

The way Guardant got it cleared is its own lesson. The company did not file a new test from zero and argue each cancer indication over again; it brought a more capable assay through the FDA and let the prior approved claims transfer. Then it put its entire portfolio on one AI-enabled foundation it calls the Smart Platform — the same architecture now underpinning tests for early screening, recurrence monitoring, and treatment selection. One cleared core, many products hanging off it. A company that spent years and millions clearing each device as a standalone fight is looking at a different playbook.

The stakes scale with the category. The U.S. liquid biopsy market sat at roughly $2.8 billion in 2026 and is forecast to approach $8.9 billion by 2035, and it is crowded — diagnostics incumbents on one side, data-first entrants like Tempus on the other. What makes this approval stand out in that field is that it bundles four advantages a competitor would normally have to win one at a time. The first is a differentiated technical claim: the multiomic read, not just a bigger panel. The second is regulatory leverage: seven approved indications that rode forward into the new assay instead of being re-litigated. The third is reimbursement, already in place across more than 300 million covered lives before the test goes to market. The fourth is platform reach: one cleared core spreading across an entire product line. Any one of those is an edge. Assembled at once, they are a moat.

For device and diagnostics teams watching from adjacent categories, the signal travels. The basis of competition in comprehensive genomic profiling is shifting from panel size to data integration. Regulatory pathways that let approved claims ride forward into a successor assay are worth designing for from the start. And the gap between a cleared test and a commercial one increasingly comes down to whether reimbursement and platform leverage were built in before the FDA ever said yes.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Cardiovascular set the tone over the past two weeks. J&J extended the Impella controller saga with a new correction tied to one death and two injuries. Boston Scientific posted positive pivotal data for its coronary IVL catheter and put $1.5 billion behind a TAVR upstart. Stryker disclosed it paid up to $835 million for Amplitude Vascular, sharpening competition in lithotripsy on multiple fronts at once. Around the edges: Medtronic and Olympus each added portfolio pieces, and the FDA cleared the first AI tool for continuous sepsis monitoring.

8 things to watch this week:

1. ⚠️ J&J Impella controller restart linked to one death, two injuries

The FDA issued an early alert after Johnson & Johnson’s Abiomed unit identified a software error that can force the Automated Impella Controller to restart for roughly 35 seconds mid-procedure, leaving patients unsupported. Abiomed sent customers updated use instructions on May 14 and is working on a software fix. The action extends a string of Impella controller corrections that began last summer.

MassDevice

2. 🧠 Medtronic to acquire SPR Therapeutics for $650M

Medtronic agreed to buy Cleveland-based SPR Therapeutics for roughly $650 million in cash, adding the FDA-cleared SPRINT peripheral nerve stimulation system to its neuromodulation portfolio. SPRINT delivers up to 60 days of temporary electrical stimulation through a percutaneous lead, giving Medtronic a minimally invasive option to intervene earlier in the chronic pain pathway. It’s Medtronic’s third major acquisition this year.

Fierce Biotech

3. 💗 Boston Scientific’s third swing at TAVR: $1.5B for a 34% stake in MiRus

Boston Scientific invested $1.5 billion for an approximately 34% equity stake in MiRus and an exclusive option to acquire the company’s SIEGEL balloon-expandable TAVR system through additional milestone-tied payments totaling $3 billion. The structure gives Boston Scientific a defined path back into structural heart after exiting the Acurate program last year — and a third attempt at TAVR after two prior failed efforts.

MD+DI

4. 💥 Stryker’s Amplitude Vascular deal valued at up to $835M

In a 10-Q filing, Stryker disclosed it paid approximately $435 million upfront for Amplitude Vascular Systems, with up to $400 million in milestone payments tied to regulatory and commercial targets. The investigational Pulse IVL system uses CO₂-generated pressure waves delivered through a balloon catheter to treat calcified peripheral arterial disease. The deal places Stryker squarely in an IVL market now contested by J&J/Shockwave, Abbott, and Boston Scientific.

MassDevice

5. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made in the sequencing — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a fast, structured external diagnostic that surfaces those gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored

6. 🔬 Boston Scientific’s SEISMIQ coronary IVL hits primary endpoints in FRACTURE

Boston Scientific reported positive pivotal results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter at EuroPCR 2026, with a 93.3% rate of freedom from major adverse cardiac events at 30 days and 93.7% procedural success across 420 patients with severely calcified coronary artery disease. The data supports a planned FDA submission and positions Boston Scientific to compete directly with J&J’s Shockwave franchise in coronary IVL.

AJMC

7. 🧬 Olympus to buy Israel’s BioProtect for $270M to expand in prostate cancer

Olympus agreed to acquire BioProtect for $270 million, picking up the company’s biodegradable balloon spacer used to separate the prostate from the rectum during radiation therapy. The device has been used in more than 11,000 procedures worldwide since its 2023 commercial launch. The deal extends Olympus’ push into oncology adjacencies after a multi-year portfolio reshaping around endoscopy and therapeutic solutions.

Medical Device Network

8. 🤖 Bayesian Health lands first-ever FDA clearance for continuous AI sepsis monitoring

The FDA granted 510(k) clearance to Bayesian Health’s TREWS platform — the first AI tool to clear the agency for continuous sepsis monitoring rather than rule-based EHR alerts. Built by Johns Hopkins researchers, the system showed 82% sensitivity for early sepsis detection in a prospective study published in Nature Medicine, and patients were 18% less likely to die in the hospital when clinicians acted on its alerts in time. Bayesian is positioning for a CMS New Technology Add-on Payment decision in early August.

24x7 Magazine

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Healthcare Fraud Enforcement Just Hit Record Highs. The DOJ Is Just Getting Started — And Device Companies Are Squarely in Frame.

While most of the medtech industry’s attention this spring has been on Marty Makary’s resignation, FDA review backlogs, and the IVL competitive fight, a quieter but arguably more consequential shift has been gathering momentum at the Department of Justice. Last week, MD+DI ran a piece warning that healthcare enforcement will “expand exponentially” under the Trump administration’s restructured enforcement apparatus. For device manufacturers, especially those operating at the kickback-and-billing seam where commercial teams meet physician customers, this is the regulatory story to be tracking.

The numbers tell the story bluntly. False Claims Act recoveries hit a record $6.8 billion in fiscal year 2025 — the highest single-year recovery in the statute’s nearly 40-year history, and more than double the $2.9 billion recovered in FY 2024. Healthcare and life sciences accounted for $5.7 billion of that, or 83 percent. Whistleblowers filed 1,297 qui tam actions, another record. The medical device industry’s specific share was roughly $76 million across five or six enforcement actions — a smaller absolute number than pharma or insurers, but the trajectory is what matters.

The infrastructure is being built quickly, and on purpose

Three things have happened in the past three months that, taken together, indicate this isn’t a one-year spike. On April 1, the DOJ stood up a new National Fraud Enforcement Division, with Colin McDonald sworn in as its first Assistant Attorney General. Acting Attorney General Todd Blanche directed the division on April 7 to take “immediate action” to become a robust litigating arm focused on fraud against taxpayer-funded programs. On April 30, the division announced the West Coast Health Care Fraud Strike Force, spanning Arizona, Nevada, and Northern California — with U.S. Attorneys in those districts specifically calling out medical device and wound care companies as targets, and Silicon Valley described as “ground zero” for technology-enabled healthcare fraud.

The infrastructure underneath is what should genuinely concern compliance officers. The DOJ’s Health Care Fraud Data Fusion Center, launched last June, uses AI and cloud computing to identify billing anomalies at scale — flagging outlier patterns before any human investigator gets involved. As one compliance expert told Medical Economics this spring, “Investigations are increasingly triggered by analytics, so practices get flagged because their data does not look like their peers.” For device manufacturers, the equivalent flags will come from utilization patterns, surgeon-specific implant volumes, and Medicare/Medicaid billing curves that diverge from the field. The first time many companies will hear about an investigation is when the subpoena arrives.

What this looks like on the ground

The clearest recent example of how an enforcement action actually plays out against a device company is the Aesculap Implant Systems settlement, announced last November but worth revisiting because it illustrates the full enforcement model now being scaled. The orthopedic and spine company agreed to pay $38.5 million to resolve allegations that, from 2010 through 2023, it sold its Vega knee replacement system knowing the implants were prone to premature loosening due to bone-cement adhesion problems — causing false Medicare and Medicaid claims for revisions. The settlement also resolved Anti-Kickback Statute allegations that Aesculap paid a Georgia orthopedic surgeon through consulting fees, international travel, and entertainment to induce him to use the device. A separate non-prosecution agreement covered the company’s distribution of two devices — a surgical drill and a sterilization container — without the required FDA clearance, after an employee forged the regulatory documentation.

Three whistleblowers split $4.475 million. The case stitched together the False Claims Act, the Anti-Kickback Statute, and the Food, Drug, and Cosmetic Act in a single coordinated resolution involving DOJ Civil Division, HHS-OIG, FDA’s Office of Criminal Investigations, and the U.S. Attorney’s Office for the Eastern District of Pennsylvania. That convergence — one company, three statutes, four agencies, three relators — is the template the new Strike Force model is built to replicate at higher velocity.

What changes for device companies

A few practical implications worth thinking through. First, the era of “paper” compliance programs is functionally over. Barnes & Thornburg’s annual report flagged that prosecutors are now actively differentiating between compliance programs that exist on a shared drive and ones that operationally function — and that distinction now matters in charging decisions and settlement leverage. Second, private equity-owned device platforms are receiving heightened scrutiny under existing Anti-Kickback and Stark frameworks, particularly where roll-up economics create incentive structures that look like volume inducements. Third, qui tam relators won more healthcare cases without DOJ intervention in FY 2025 than with it — the first time that’s happened — which means even matters DOJ declines can still produce nine-figure recoveries.

The strategic takeaway is straightforward. The FDA-side regulatory burden has been the medtech industry’s dominant compliance focus for a generation. The DOJ-side enforcement burden has now caught up, and it’s arriving with better data infrastructure, more aggressive prosecutorial posture, and a whistleblower pipeline that filed at record volume last year. For device companies whose commercial models touch surgeon relationships, billing intermediaries, or Medicare/Medicaid reimbursement — which is most of them — the next 12 months are a moment to pressure-test compliance programs against the way enforcement is actually being run today, not the way it was five years ago.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. ⚖️ Makary out at FDA after 13 tumultuous months

Marty Makary resigned as commissioner of the Food and Drug Administration Tuesday, ending a 13-month tenure marked by turmoil, with Kyle Diamantas, the FDA’s top food regulator — who does not have a medical degree — stepping in as acting commissioner. Expect another stretch of agency uncertainty for sponsors managing review timelines, advisory committee scheduling, and pending AI/CDS guidance. NPRU.S. News & World Report

NPR

2. 🌐 Trade court rules Trump’s 10% global tariff unlawful

A 2-1 panel of the Court of International Trade concluded the Trump administration misread the law used to justify the sweeping tariffs, but an appeals court has since paused the ruling pending DOJ challenge. Medtech finance teams should still plan for tariff drag in their 2026 guidance — the underlying levy remains in force for now. ABC News

ABC News

3. 🎯 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a fast, structured external diagnostic designed to surface those gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored

4. 💸 Stryker closes Amplitude Vascular deal at up to $835M

Stryker paid approximately US$435 million upfront, with the agreement also including up to US$400 million in future milestone-based payments for Amplitude’s CO₂-generated pressure wave IVL platform, putting Stryker into a peripheral arterial disease market already populated by J&J, Boston Scientific, and Abbott. Tuck-ins around hot procedure categories remain the dominant M&A pattern of 2026. FW Africa

Endovascular Today

5. 📊 Elliott lands two board seats at Dexcom

Dexcom agreed to grant Elliott Investment Management, one of its largest shareholders, two independent seats on its board, with the existing technology committee being reconstituted as an operations and innovation committee with added quality oversight. After Elliott’s earlier run at Medtronic, this is now a recognizable playbook — and a signal to other large-cap medtechs about portfolio focus and execution discipline. Seeking Alpha

Seeking Alpha

6. 🤖 Bayesian Health wins first FDA clearance for continuous AI sepsis monitor

The Johns Hopkins spinoff’s Targeted Real-time Early Warning System (TREWS) became the first continuous AI sepsis monitor to gain FDA approval, having already been deployed at Cleveland Clinic, University of Rochester Medicine, and MemorialCare under breakthrough designation. Worth tracking as a real-world test of how always-on AI surveillance gets reimbursed, embedded in EHRs, and audited post-market — Bayesian is targeting NTAP reimbursement starting October. Beckers Hospital Review

Becker’s Hospital Review

7. 🫀 J&J launches Shockwave C2 Aero coronary IVL globally

The next-generation catheter is designed for improved deliverability, enhanced lesion crossing, and new repositioning capabilities for the treatment of calcified coronary artery disease, and is now available in the United States and Japan, with additional markets in the months ahead. Timing is no accident — it lands days before EuroPCR in Paris and just as Stryker’s Amplitude deal closes. Iteration cadence will set the tempo of the IVL competitive set.

Cardiovascular Business

8. 🇩🇪 Carl Zeiss Meditec to cut up to 1,000 jobs

The German ophthalmic and microsurgery giant plans to reduce its workforce by up to 1,000 over the next few years after revenues fell 5.7% YoY and earnings dropped nearly 66% in fiscal H1. Combined with Medtronic’s Santa Rosa site closure the week prior, the message is consistent: even healthy medtechs are tightening operating footprints heading into the back half of 2026. MassDevice

MassDevice

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

FDA Commissioner Marty Makary Just Resigned. Here's What His Exit Actually Means for Medical Device Companies.

On Tuesday, May 12, Marty Makary resigned as Commissioner of the Food and Drug Administration after 13 months in the role. Politico first reported the resignation; President Trump confirmed it in remarks to reporters at the White House before departing for China, and Kyle Diamantas, the agency’s Deputy Commissioner for Food, was named acting commissioner. Diamantas is a lawyer with no medical training — an unusual profile for the role. Names reported under consideration for the permanent position include former Commissioner Stephen Hahn, who led the agency from 2019 to 2021, and former acting Commissioner Brett Giroir.

Most of the immediate coverage has framed the resignation around the proximate trigger — the fruit-flavored e-cigarette authorization the FDA issued last week, which Makary reportedly opposed — and the political pressure he faced from anti-abortion groups over mifepristone. Both matter. Neither is the most important angle for medtech.

For medical device companies, Makary’s 13-month tenure produced two things, and they pull in opposite directions.

The reform agenda

Makary was the FDA half of the most significant medtech regulatory development of the past year. The Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, announced in late April as a joint initiative with CMS Administrator Mehmet Oz, was designed to close the median six-year gap between FDA breakthrough authorization and Medicare coverage. His other speed-oriented initiatives during the tenure included expanded use of the National Priority Voucher Program, draft AI lifecycle management guidance issued in January 2025, and a stated emphasis on de novo flexibility — the same pathway J&J used to file for Ottava authorization in January.

By the official metrics, device review has held. CDRH Director Michelle Tarver, who has remained in her role through every leadership upheaval at the agency since her permanent appointment in October 2024, told the MedCon conference last month that the device center authorized 124 new devices in 2025, the third-highest total in CDRH’s history.

The capacity problem

Against that record, Makary inherited and oversaw an FDA that has lost roughly 21 percent of its workforce — more than 4,400 people — between September 2024 and January 2026, according to Office of Personnel Management data analyzed by MedTech Dive. The CDRH was hit in two rounds of firings in February and April of last year; by August, a ProPublica analysis put device center staff losses at more than 20 percent due to cuts and attrition combined.

By April of this year, the strain was no longer abstract. A five-part series published on April 1 by MedTech Dive reporters Elise Reuter and Shaun Lucas interviewed current and former CDRH staff, regulatory attorneys, and consultants who described an agency under sustained pressure. Kelliann Payne, a Hogan Lovells partner specializing in medical devices, told them: “I’ve been writing premarket submissions and interacting with FDA since the late 90s, and this is by far the most volatile up and down, delays in timing that I’ve seen.” Sean Boyd, the former director of CDRH’s Office of Regulatory Programs, described a “culture of fear and anxiety.” Attorneys at Cooley and Arnold & Porter described pre-submission meetings producing inconsistent feedback, mid-application reviewer changes that reset positions taken by earlier reviewers, and deficiency letters arriving with less detail than companies had come to expect.

The reforms Makary authored and the capacity crisis he presided over are not separable. The RAPID pathway, the AI guidance, the de novo pace — every one of them is downstream of whether CDRH has enough trained reviewers to execute. An HHS spokesperson told MedTech Dive in April that the FDA is hiring “more than 1,000 reviewers, inspectors and investigators,” but Boyd noted that training a new CDRH reviewer takes two to three years.

What to watch

Three questions are now open for medtech. The first is succession. Diamantas is acting, not permanent, and his food-and-tobacco profile is a poor fit for the medtech beat. A Hahn-style return would signal continuity with traditional industry expectations on review predictability; a different profile could push CDRH in a different direction. The second is Tarver — she has been the point of stability for the device center through fourteen months of agency turmoil. Whether she remains under the next commissioner is the single most important continuity question for the industry, because she is the operating leader who actually moves the work. The third is the fate of the in-flight pathway implementations: RAPID’s operational details, the final AI lifecycle guidance Tarver previewed at AAMI neXus on April 17, and the de novo backlog that pending submissions like Ottava are entering.

What Makary’s resignation does not change is the structural fact that the agency reviewing medical devices is doing the same work with significantly fewer people than it had eighteen months ago. The Commissioner is gone. The capacity question is not.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The week told two stories at once. On one side, AI-driven consolidation accelerated as Roche put a real number on the digital pathology market and Google pushed deeper into ambient consumer health. On the other, incumbents kept restructuring under pressure: Siemens Healthineers trimmed guidance and floated a Diagnostics spinoff, Medtronic announced it will close a 28-year-old California site, and the FDA flagged a new supply shortage that will hit OR-dependent product lines through year-end. The throughline: the platforms that can absorb AI and reorganize fast keep widening their lead, and everyone else is in catch-up mode.

8 things to watch this week:

1. 🤝 Roche to acquire PathAI for up to $1.05B

Roche signed a definitive deal Thursday to acquire Boston-based digital pathology firm PathAI for $750M upfront plus up to $300M in milestones, bringing in-house an AI partner it has worked with since 2021. The deal signals that diagnostics consolidation around AI is moving from collaboration to ownership — and validates premium valuations for AI-enabled diagnostic platforms with established commercial traction.

MedTech Dive

2. 📉 Siemens Healthineers cuts 2026 outlook, opens door to Diagnostics carve-out

Citing a 6.5% revenue decline in Chinese diagnostics and pronounced inflation, Siemens trimmed FY2026 revenue growth guidance to 4.5–5% (from 5–6%) and announced a leadership reshuffle on May 7. CEO Bernd Montag said the company is “initiating the next steps to create options for Diagnostics” — strategy-speak markets are reading as a potential carve-out, with major implications for the global IVD landscape.

MassDevice

3. ⌚ Google launches $99 screenless Fitbit Air; rebrands app to Google Health

Google unveiled the Fitbit Air on May 7 — a 12-gram screenless tracker built around Gemini AI’s Health Coach with AFib detection, SpO2, HRV, and skin temperature tracking, all without a required subscription. The Fitbit app becomes “Google Health” on May 19, signaling Big Tech’s continued push toward a regulated-adjacent consumer health stack and intensifying pressure on Whoop, Oura, and traditional wearables alike.

TechCrunch

4. 🎯 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a fast, structured external diagnostic designed to surface those gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored

5. 💉 Tandem to file tubeless Mobi insulin pump 510(k) this quarter

On its May 8 earnings call, Tandem said it will file a 510(k) for a tubeless version of its Mobi pump this quarter, with clearance expected in 2H 2026 and a phased launch to follow. The move targets the ~20% growth tubeless segment currently dominated by Insulet — and gives clinicians a single platform that can switch between tubed and tubeless wear, a first in the category.

MedTech Dive

6. 🏭 Medtronic to close Santa Rosa operations, relocate 370 jobs by 2028

Medtronic informed Santa Rosa employees on May 7 that it will fully exit the California site over the next two years, shifting production primarily to Santa Ana, Minneapolis-area facilities, and Galway, Ireland. The wind-down ends a 28-year footprint that began with the $3.7B Arterial Vascular Engineering acquisition — and continues the consolidation playbook large medtechs are running to offset tariffs and protect margin.

Press Democrat

7. ⚠️ FDA warns of neurosurgical sponge and patty shortages through 2026

The FDA added neurosurgical patties, sponges, and strips to its device shortage list on May 6 following Medline’s recall of products with elevated endotoxin levels. The disruption affects fluid-absorbing devices used across cranial and spine procedures, and the agency expects supply pressure to persist through year-end — a procedure-volume risk for OR-dependent product lines.

MedTech Dive

8. 🧠 FDA clears first at-home brain stimulation device for major depression

Flow Neuroscience’s FL-100 transcranial direct-current stimulation system received FDA authorization, becoming the first prescription at-home tDCS device cleared in the U.S. for moderate-to-severe MDD in adults — as monotherapy or adjunct. Launch is targeted for Q2 via iOS and Android, opening a new neuromodulation category and pressuring both pharmaceutical antidepressants and clinic-bound neuromodulation incumbents.

Patient Care Online

BONUS STORY

🔒 Cybersecurity now the top driver of FDA premarket rejections

Industry experts headlining MedTech World North America (May 11–13, West Palm Beach) say premarket rejection rates have surged since the FDA finalized its updated cybersecurity guidance in February. The signal for connected-device makers: SBOMs, threat modeling, and post-market vulnerability management aren’t a final-checklist item — they’re a gating design input, and capital is sitting on the sidelines waiting for clarity.

Note: Check out the talk by MedTech World title sponsor and speaker Cristian Espinosa (founder and CEO at Blue Goat Cyber) on the topic this week!

Weekly Voice / MedTech World

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

J&J's Ottava Just Posted Its First Clinical Data. Here's What It Actually Means for Soft-Tissue Robotics.

For more than two decades, soft-tissue robotic surgery has effectively been one company’s market. Intuitive Surgical received the first FDA clearance for general laparoscopic surgery with the da Vinci system in 2000, and by every reasonable estimate has held onto the clear majority of the global market ever since — most recently around 60 percent, according to GlobalData. Hospitals built training programs around da Vinci, surgeons were trained on da Vinci, and competitors that tried to enter the category mostly faded or remained regional. That has begun to shift — Medtronic’s Hugo received its first U.S. clearance in urology in December 2025, CMR Surgical’s Versius platform crossed 40,000 procedures globally this spring — but the most-watched challenger has been Johnson & Johnson, which announced its Ottava program in 2020 and has been mostly quiet ever since.

On May 5, J&J presented the first clinical data on Ottava at the American Society for Metabolic and Bariatric Surgery annual meeting in San Antonio. The FORTE study enrolled 30 patients across six U.S. hospitals, all of whom were undergoing Roux-en-Y gastric bypass. The system met its primary safety and performance endpoints at 30 days. All 30 procedures were completed robotically without conversion to a non-robotic approach. J&J said the data, combined with preclinical work, support the de novo classification application it submitted to the FDA in January for general surgery, including gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair.

The path to that data has been longer than J&J originally projected. The company unveiled Ottava in 2020, delayed development by approximately two years in late 2021, submitted for an Investigational Device Exemption in October 2024, received FDA approval of that IDE the following month, and completed its first cases in April 2025. The FORTE cohort is a feasibility study, not a pivotal trial, and the 30-day window is a safety threshold rather than a comparative efficacy endpoint. Whatever Ottava ultimately becomes commercially, the May 5 announcement is a milestone inside an FDA submission process — not a market launch.

The Architecture Bet

What separates Ottava from the systems already on the market — and what makes the FORTE results worth a closer look than the headline numbers — is the physical design. Da Vinci, Hugo, and Versius all use cart-based or boom-mounted arms positioned next to the patient. Ottava integrates four robotic arms into a standard-sized surgical table. There is no separate robot to wheel into the room.

In FORTE, the operating rooms ranged from approximately 243 to 694 square feet. According to J&J, in five of the six sites, procedures were performed in ORs that had not previously hosted robotic surgery. That is the strategic claim the company is making: not that Ottava performs better than da Vinci, but that it fits in places da Vinci cannot easily go. Intuitive’s installed base advantage — built up over more than two decades of placements — has rested on the implicit assumption that the hospital adapts to the robot. Ottava is being positioned around the inverse assumption.

That reframing matters because the largest unaddressed segment of soft-tissue robotics is not academic medical centers, where da Vinci is already entrenched. It is the ambulatory surgery centers and community hospitals that have been priced out or space-constrained out of robotic surgery entirely. ASCs have been shifting volume away from inpatient settings for over a decade, and robotic soft-tissue surgery has largely not kept pace. If Ottava can be installed in ORs that smaller facilities already have — and J&J’s data suggests it can — the addressable market for soft-tissue robots looks different from the one Intuitive has spent 25 years building.

The Open Questions

The FORTE data does not establish that Ottava performs as well as da Vinci or as well as Hugo. It establishes that Ottava can safely perform gastric bypass in 30 patients within 30 days. The de novo submission is also broader than what was studied clinically — J&J is asking the FDA to authorize Ottava for procedures not yet evaluated in human trials, supported by preclinical work and the FORTE data as a feasibility benchmark. De novo decisions typically take longer than 510(k) reviews, and the FDA’s device center has been operating with reduced staffing through 2025 and into 2026, which has slowed reviews across the medtech sector.

There are also market headwinds specific to bariatric surgery, the lead indication J&J chose to study. GLP-1 medications have introduced new pressure on surgical weight loss volume over the past two years. Roux-en-Y was a sensible choice for a feasibility study — the procedure is well standardized and well instrumented for robotic comparison — but the long-term commercial argument for Ottava will rest more on its other indications, particularly hernia repair and small bowel resection, and on whatever specialties J&J pursues in subsequent submissions.

The company has not disclosed pricing or a commercial timeline. Intuitive, meanwhile, is two years into the rollout of da Vinci 5, which adds force-feedback instrumentation and computational features the previous generation lacked. The architectural argument Ottava is making is compelling on paper. Whether hospitals — particularly the ASCs and community systems that the system appears implicitly built for — adopt it on those terms is a question the FORTE data does not yet answer.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The theme this week is competition — in the OR, in the EP lab, and in the supply chain. Robotics is heating up on multiple fronts, the AThe fib ablation market is fragmenting fast, and the US-China tariff truce is giving device manufacturers a window to reset their strategy. Here’s what matters this week.

8 things to watch this week:

1. 🤖 J&J Releases First Clinical Data for OTTAVA Robotic System, Files for FDA De Novo Clearance

Johnson & Johnson today presented first-in-human clinical results from its OTTAVA robotic surgical system at the ASMBS Annual Meeting in San Antonio. In a 30-patient multicenter cohort evaluating Roux-en-Y gastric bypass, the system met all primary safety and performance endpoints through 30 days post-procedure — and was successfully deployed in ORs as small as 243 sq. ft., including rooms never previously used for robotic surgery. J&J simultaneously filed a De Novo classification request with FDA targeting multiple upper abdominal procedures. With da Vinci’s dominance long unchallenged in soft tissue, a credible competitor just got a lot more credible.

Business Wire / Yahoo Finance

2. 🎯 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis (Commercial Launch Impact Framework) from RŌG Health is a fast, structured external diagnostic designed to surface those gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored

3. 🌐 US-China Tariff Truce Gives MedTech Manufacturers Room to Breathe — For Now

The US and China reached a partial trade agreement in early May, rolling back tariffs on a broad range of industrial goods, including medical device components — sensors, precision instruments, plastics, and metals that had faced duties as high as 145% at peak. For medtech startups and scale-ups in particular, the deal provides a more predictable cost environment. But the clock is running: it’s a 90-day pause, USTR Section 301 public hearings on broader manufacturing tariffs are scheduled this week, and AdvaMed CEO Scott Whitaker is still pressing for a permanent “zero for zero” reciprocal tariff policy. Relief is real. Permanence is not.

BIOMEDevice Boston / MedDeviceGuide

4.💓 HRS 2026: Pulse Biosciences’ Nanosecond PFA Data Turns Heads in Electrophysiology

At Heart Rhythm Society 2026 in Chicago last week, Pulse Biosciences presented updated data from its nPulse Cardiac Catheter first-in-human European feasibility study: 100% procedural success at 6 months (95/95 patients), 96% at 12 months (51/53), and 90% Kaplan-Meier freedom from atrial arrhythmias at one year — with a total procedure time averaging just over 60 minutes. The company also confirmed it has commenced enrollment in its US IDE pivotal trial, with completion now targeted for early Q4 2026. In a PFA market currently dominated by Medtronic, Boston Scientific, and Abbott, the nanosecond PFA approach is generating genuine attention as a potential next-generation differentiator.

Pulse Biosciences IR / BioSpace

5. ⚡ HRS 2026: Abbott and Boston Scientific Both Stake Their PFA Ground in a Crowded EP Market

Also at HRS 2026, Abbott presented six-month IDE data for its TactiFlex Duo Ablation Catheter, showing positive outcomes in complex AFib cases, as well as first-in-human data for its investigational AVEIR CSP leadless pacemaker system. Boston Scientific countered with positive data from the Farapulse PFA and Watchman LAAC. With Medtronic’s PulseSelect, Abbott, BSX, Kardium, and now Pulse Biosciences all competing in the pulsed field ablation space, HRS 2026 underscored how rapidly this market is fragmenting — and provides useful context for Boston Scientific’s surprising guidance cut the week prior.

Abbott / Boston Scientific via PR Newswire / MDDI

6. 💤 SleepRes Wins FDA 510(k) Clearance for Adaptive PAP Device Targeting CPAP’s Adherence Problem

SleepRes received FDA 510(k) clearance this week for its Kricket PAP device, which uses Kairos technology to dynamically adjust pressure throughout the breathing cycle — in contrast to traditional fixed-pressure CPAP. The device is cleared for home, hospital, and sleep center use in patients over 66 lbs, with commercial launch planned for H1 2026. CPAP adherence remains one of sleep medicine’s most persistent unsolved problems, and adaptive pressure technology represents a meaningful clinical differentiation play in a large, underpenetrated market.

Medical Economics

7. ⚠️ U.S. Hospital Dependence on Chinese-Manufactured Devices Poses Security Risk, Expert Warns

A medical device security expert flagged in a May 4 MDDI report that US hospital dependence on Chinese-manufactured devices presents supply chain security vulnerabilities that extend beyond cost, raising concerns about geopolitical exposure in critical care settings. The issue is particularly acute for imaging systems, monitoring equipment, and disposables, where Chinese manufacturing share remains significant. The warning lands in the same week as USTR Section 301 hearings and is a reminder that the tariff conversation has dimensions that go beyond input costs.

MDDI

8. 🏛️ FDA Announces Major Steps to Implement Real-Time Clinical Trials

On April 28, the FDA announced concrete steps toward implementing real-time clinical trial infrastructure — a framework designed to accelerate the generation, review, and action on evidence for medical devices and combination products. This initiative follows the RAPID coverage pathway announcement the prior week and reflects the current administration's ongoing effort to compress approval and coverage timelines. For device companies now designing pivotal trials, the signal is worth building into their protocol and evidence-generation strategy.

FDA.gov

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The FDA and CMS Just Launched a New Breakthrough Device Coverage Pathway. Here’s What It Actually Covers.

For years, one of medtech’s most persistent frustrations has been the gap between FDA authorization and Medicare coverage. A device can clear the FDA’s most rigorous review, demonstrate clinical efficacy in a pivotal trial, and still wait a year or more — sometimes much longer — before CMS issues a National Coverage Determination. According to a 2022 survey from the Stanford Byers Center for Biodesign and the Duke-Margolis Center for Health Policy, the average time from FDA authorization to national Medicare and commercial coverage is five years.

On April 23rd, CMS and FDA announced a new attempt to close that gap. The Regulatory Alignment for Predictable and Immediate Device coverage pathway — RAPID — is designed to bring the two agencies into alignment earlier in the development process, so that evidence generated for FDA review can also satisfy Medicare coverage requirements. Under the pathway, CMS would issue a proposed NCD the same day an eligible device receives FDA marketing authorization. The 30-day public comment period would follow, and national coverage could take effect as soon as two months after authorization — down from a year or more today.

The agencies have tried versions of this before. The FDA’s Parallel Review Program launched as a pilot in 2011 and was fully implemented in 2016; as of late 2024, 97 devices had requested participation, and two had completed it. The first Trump administration’s MCIT rule offered four years of automatic Medicare coverage upon FDA authorization, but was scrapped by the Biden administration, which replaced it with the Transitional Coverage for Emerging Technologies pathway in 2024. TCET was capped at 5 devices per year, even though the FDA typically grants more than 100 breakthrough designations in that time. AdvaMed criticized TCET for exactly that reason. TCET is now paused as CMS shifts focus to RAPID.

The Eligibility Gap

This is where the announcement warrants careful reading. RAPID is not available to all breakthrough devices. Class III breakthrough devices qualify regardless of additional program participation. Class II breakthrough devices qualify only if they are enrolled in FDA’s Total Product Life Cycle Advisory Program, or TAP — an enhanced engagement program initiated under MDUFA V. All eligible devices must also be the subject of an Investigational Device Exemption study that enrolls Medicare beneficiaries and studies clinical outcomes agreed upon by both agencies. That IDE requirement alone excludes non-significant risk devices, which make up the majority of the Class II market.

A senior CMS official said on the day of the announcement that approximately 40 devices currently qualify, with another 20 potentially eligible. For context: as of December 30, 2025, FDA had granted 1,246 Breakthrough Device Designations, with 185 devices having received marketing authorization. More than 1,000 breakthrough-designated devices remain outside the pathway’s reach under the same coverage dynamics as before. As Jennifer Newberger of Hyman, Phelps & McNamara wrote in a post-announcement analysis, RAPID may function as “less a systemic solution than a targeted pilot for a narrow slice of the market.”

Industry Response and What to Watch

AdvaMed called RAPID a “positive step” but stopped short of an endorsement, with CEO Scott Whitaker noting that “without meaningful timelines, accountability, and effective management of this program, patients are unlikely to see the full benefits of new technologies.” Whitaker also flagged a complicating factor: CMS has separately proposed repealing the New Technology Add-on Payment alternative pathway for breakthrough devices, which provides temporary reimbursement supplements to hospitals offering procedures with newly authorized technologies. NTAP and RAPID serve different but complementary roles in the access equation, and industry is watching both simultaneously.

The proposed procedural notice will be published in the Federal Register, opening a 60-day public comment period. RAPID does not take formal effect until CMS issues a final notice in response to those comments. How the agencies respond to stakeholder input — particularly on whether TAP participation should remain a prerequisite for Class II eligibility — will determine whether RAPID stays narrow or expands its reach. For companies that do qualify, the most immediate implication is practical: trial design conversations with CMS should begin earlier than they have historically, and IDE protocols should be structured with Medicare outcomes in mind from the start.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🏛️ CMS & FDA Launch RAPID Coverage Pathway for Breakthrough Devices

CMS and FDA jointly unveiled the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, which could compress Medicare coverage timelines for breakthrough devices from over a year down to as little as two months. Roughly 40 existing devices qualify immediately — and with permanent Medicare coverage on offer (not the four-year window of prior programs), this fundamentally changes the commercial calculus for companies building toward a breakthrough designation.

FierceHealthcare

2. 🎯 86% of Medtech Teams Make Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.

Take the free readiness check →

Sponsored

3. 🤖 Intuitive Surgical Posts Blowout Q1, Raises Full-Year Guidance

Intuitive reported $2.77B in Q1 revenue (+23% YoY), beating consensus by ~5.5%, with EPS of $2.50 crushing estimates by nearly 17%. Da Vinci procedure volume grew 16% and Ion surged 39%. Management raised its full-year procedure growth outlook and shares jumped more than 7% — the clearest signal yet that surgical robotics demand is not slowing down.

Proactive Investors

4.📉 Boston Scientific Slashes 2026 Guidance Despite Solid Q1

BSX posted solid Q1 revenue of $5.2B (+11.6%), but dramatically cut its full-year sales growth forecast from 10.5–11.5% down to 7–8.5%, citing unexpected headwinds in its Farapulse PFA platform, Watchman, and Urology franchises. Competitors Medtronic, J&J MedTech, Abbott, and Kardium are all gaining ground in electrophysiology — and CEO Mike Mahoney called the guide-down something the company was “not proud of.”

MedTech Dive

Before we continue — quick question for you:

Thanks — now back to the news.

5. 💊 Johnson & Johnson MedTech Grows 4.6% in Q1, Raises Full-Year Guidance

J&J’s MedTech segment posted $8.6B in Q1 sales with 4.6% operational growth, driven by cardiovascular, surgery, and vision. The company raised its full-year 2026 operational sales guidance to 5.9–6.9%, targeting $100B+ in total company revenue — and its OTTAVA robotic surgery system is now a credible threat to Intuitive Surgical in the multi-port segment by late 2026.

Yahoo Finance / GuruFocus

6. 🤝 Stryker Acquires Amplitude Vascular; Avanos Goes Private in Active M&A Week

Stryker announced its acquisition of Amplitude Vascular Systems (IVL-based vascular technology) in a week that also saw Avanos Medical agree to be taken private at a 72% premium. Zooming out: Q1 2026 medtech M&A totaled $26.6B across 37 deals — with deal flow accelerating around surgical robotics, cardiovascular, and diagnostics — signaling that strategic portfolio reshaping remains a defining theme of the year.

FierceBiotech / J.P. Morgan

7. ⚠️ FDA Issues Class I Recall for Tandem Mobi Insulin Pumps Over Software Flaw

The FDA classified a software correction for Tandem’s Mobi insulin pump as a Class I recall — its most serious designation. A false motor detection error can halt insulin delivery entirely, risking severe hyperglycemia. Over 17,700 devices are affected and users are urged to update to software version 7.9.0.2 immediately. This is the latest in a string of diabetes device safety actions from the FDA in 2026, including a prior Insulet Omnipod 5 recall in March.

MedTech Dive / FDA

8.💡 AcuityMD Raises $80M Series C, Valued Near $1B

AcuityMD, the AI commercial intelligence platform used by 16 of the top 20 medtech companies, raised $80M in a Series C led by StepStone Group. The company — which has helped customers identify more than $34B in pipeline opportunities — plans to accelerate agentic AI for sales and marketing teams and expand beyond commercial use cases across the full product lifecycle. With the medtech sector increasingly competing on commercial execution, this signals where the next wave of operational investment is headed.

The AI Insider

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Stereotaxis to buy Robocath for up to $45M

Stereotaxis has agreed to acquire robotic PCI developer Robocath in a deal valued at up to $45 million, adding coronary intervention capabilities to a platform historically focused on electrophysiology.

The transaction includes $20 million upfront and up to $25 million in milestone-based payments tied to regulatory and commercial progress, including FDA clearance of Robocath’s next-generation system. That structure reflects both the strategic intent and the remaining execution risk, particularly in the U.S. market, where Robocath does not yet have approval.

At the product level, the companies bring distinct technologies. Stereotaxis has built its business around magnetic navigation systems used primarily in cardiac ablation — its Synchrony platform, which recently received FDA clearance, and the broader GenesisX and SynX ecosystem give the company proprietary building blocks for the integration ahead. Robocath’s R-One+ platform enables robotic manipulation of guidewires and devices during percutaneous coronary interventions. The system is CE marked and in limited commercial use outside the United States, with 15 systems installed globally. Clinical data from the multicenter R-EVOLUTION study showed 100% clinical success and 95.2% technical success across 62 patients with no complications at 30 days, though the study authors noted that larger populations and more complex lesion profiles will be needed before the evidence base is considered mature.

The rationale for combining those capabilities points to a broader shift in how robotic intervention is developing.

For much of the past decade, systems in this category have been designed around individual procedures, with companies attempting to establish clinical and economic value within narrowly defined use cases. The most established robotic PCI system in the U.S. market — Siemens Healthineers’ CorPath GRX — reflects that approach: a capable, cleared platform that has built its case specifically in interventional cardiology. Stereotaxis is taking a different position. By adding PCI and positioning for eventual expansion into neurovascular intervention, the company is moving toward a multi-procedure platform that can be deployed across service lines rather than anchored in a single specialty.

That strategy reflects a view that the barrier to adoption in robotic intervention is no longer primarily technical. It is structural — tied to workflow integration, physician training, and the ability to support consistent procedural volume.

Whether this acquisition addresses those constraints is less clear.

Integrating magnetic navigation and mechanical robotic control into a unified system presents practical challenges. The technologies operate differently, require different forms of physician interaction, and have been developed for distinct clinical settings. Stereotaxis has existing proprietary hardware and software infrastructure to build from, but bringing them together in a way that simplifies, rather than complicates, use in the cath lab will be critical. The company has projected Robocath will contribute roughly $2 million in revenue in the first year post-acquisition, with breakeven expected by the third year — figures that underscore just how early this integration is in commercial terms, even as the strategic logic is clear.

The regulatory timeline adds another layer of uncertainty. Robocath’s current platform is not approved in the U.S., and future clearance is already embedded in the deal’s economics. Stereotaxis has indicated it plans to pursue regulatory submissions in both the U.S. and Europe within two years. Until that milestone is achieved, the platform Stereotaxis is building remains only partially realized in its largest potential market.

The deal ultimately sits within a broader inflection point for robotic intervention in medtech.

Companies are beginning to move away from procedure-specific systems toward platforms that can support a wider range of interventions. The logic is straightforward: broader applicability can support higher utilization, and higher utilization is what justifies adoption. At the same time, expanding platform scope introduces new complexity — in integration, in training, and in demonstrating consistent value across different clinical contexts.

Stereotaxis is effectively placing a bet on which of those forces will dominate.

If a broader platform can translate into more routine use, this type of consolidation could accelerate adoption across interventional cardiology and adjacent fields. If not, the risk is that added capability increases system complexity without materially changing how often these technologies are used.

That dynamic extends beyond a single transaction. It is increasingly central to how the next phase of robotic intervention in medtech will be defined.

SPONSORED BY RŌG HEALTH

86% of Medtech Teams Have Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.

Take the free readiness check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🏛️ CMS proposes repeal of add-on payment path for breakthrough devices

CMS is proposing to eliminate a payment pathway that was designed to help breakthrough devices gain traction in the hospital setting. For emerging medtech companies, that raises the stakes on reimbursement planning and could make commercialization even harder for products that already face long adoption cycles.

Healthcare Dive

2. 🎯 86% of Medtech Teams Make Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you're heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.

Take the free readiness check →

3. 💰 Abbott trims 2026 profit forecast on Exact Sciences deal impact

Abbott’s reduced outlook is a reminder that even large strategic transactions can create real near-term pressure before the market rewards the longer-term rationale. For medtech leaders, it’s another signal that portfolio expansion still has to clear the test of integration, margin discipline, and investor confidence.

Reuters

4. 🤝 AIP to acquire Avanos Medical in $1.27B go-private deal

A $1.27 billion take-private deal is the kind of headline that gets attention across the industry, especially as private equity continues to hunt for medtech assets with room for operational improvement. It also reinforces that strategic value in medtech is still being found well beyond the venture-backed startup class.

MedTech Dive

5. 🧠 GE HealthCare, RadNet expand AI mammography collaboration

AI in imaging keeps moving from concept to commercial workflow, and this expanded mammography collaboration is a strong example of where that momentum is showing up. The broader takeaway is that enterprise-scale AI adoption in diagnostics is increasingly being driven by partnerships with clear clinical and operational use cases.

MedTech Dive

6. 📊 FDA and industry close in on MDUFA VI user-fee agreement

The next user-fee agreement will shape review capacity, timelines, and regulatory expectations for years to come, which makes this a closely watched development even if it is less flashy than an acquisition or recall. For device makers, this is one of those policy signals that quietly affects everything from planning assumptions to submission strategy.

MedTech Dive

7. ⚠️ Medline recalls angiographic syringes, receives FDA warning letter

Recalls paired with an FDA warning letter tend to draw attention because they combine immediate operational risk with reputational exposure. Beyond the headline, this is another reminder that quality system weaknesses can quickly become commercial problems, not just regulatory ones.

MedTech Dive

8. 🤖 Stereotaxis to acquire Robocath

Robotic intervention remains one of the more compelling strategic themes in medtech, and this deal gives Stereotaxis a broader footprint in that race. It is a meaningful signal that companies in procedure-driven categories still see platform consolidation as a faster path to relevance than building everything organically.

Endovascular Today

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Luminai Raises $38 million Series B to Scale Intelligence Across Health System Operations

By now, the market has heard a thousand versions of the healthcare AI pitch. Scribes. Copilots. Chatbots. Summarizers. What is getting more interesting now is where capital is actually landing: not at the clinical edge first, but in the operational middle of the system, where referrals, compliance, access, and revenue workflows still run through faxes, PDFs, and fragmented data. That is the real signal inside Luminai’s $38 million Series B.

This is why the Cleveland Clinic angle matters more than the financing headline itself. Luminai’s partnership with the system — one that sees roughly 15 million patients annually — spans access, revenue cycle, compliance, and referrals. But if referral management is where the deployment is taking root first, as reported context suggests, it is telling you something about where the pain is. Referral workflows are high-volume, messy, labor-intensive, and directly tied to patient access. They are also full of exactly the kind of unstructured information traditional software has never handled particularly well.

Luminai’s bet is that healthcare does not need another point solution so much as it needs software that can interpret that mess, structure it, route it, and keep the process moving with human oversight when confidence falls short. In other words, this is not an AI-as-feature story. It is an AI-as-infrastructure story.

That distinction matters because the commercial logic here is unusually strong. Administrative waste in U.S. healthcare is still massive, and the case for attacking it has become much easier to make inside provider organizations under financial pressure. If a company can remove even part of the invisible manual labor that keeps referrals and back-office processes from stalling, the value proposition is immediate.

But this is also where the story gets more interesting — and more complicated — than a standard funding announcement. PHTI’s April 2026 report on administrative AI makes the point bluntly: administrative AI is advancing quickly, especially in areas like prior authorization and billing, but automation layered onto flawed workflows does not automatically reduce system-level costs. Sometimes it just makes every side faster at doing the same bureaucratic dance.

That is the bigger question hanging over this category. Can administrative AI actually simplify healthcare, or is it going to become the next arms race, where providers automate submissions, payers automate reviews, and complexity survives with better response times? Speed is valuable. But speed and simplification are not the same thing.

Luminai may have chosen a smart beachhead. Referrals are politically cleaner than some of the more contentious administrative categories, and the outcomes are easier to see. If intake improves, wait times shorten, staff time gets redeployed, and patient access gets smoother, health systems can feel the result before they have to model the downstream economics. That makes referral management a credible proving ground for the broader thesis.

This is also why the story likely resonated so strongly with your readers. The market has no shortage of AI headlines right now, but relatively few of them are anchored in the hidden operating layer that determines how patients actually move through a health system. For medtech and health-tech leaders, that layer matters more than it gets credit for. It shapes adoption, throughput, staffing strain, and ultimately how fast innovation reaches the point of care.

So the real takeaway this week is not simply that another healthcare AI company got funded. It is that the next meaningful battleground may be operational infrastructure, and buyers are beginning to treat it that way. The question now is not whether health systems want administrative AI. They clearly do. The question is whether companies like Luminai can prove that the category removes friction rather than just processing it faster. That is what would turn this from a hot funding story into a lasting healthcare story.

SPONSORED BY RŌG HEALTH

86% of Medtech Teams Have Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, this is the window to find out. We’re accepting a small number of medtech teams now.

See if you qualify →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

This week’s signal: neurovascular innovation and commercialization readiness are moving in parallel — with major acquisitions, fresh capital, and regulatory wins shaping who scales next.

8 things to watch this week:

1. 🧠 Stryker to Acquire Amplitude Vascular Systems

Stryker’s move into next-generation intravascular lithotripsy is a meaningful portfolio expansion in peripheral vascular, especially as calcified PAD remains a stubborn procedural challenge. For medtech leaders, this is another reminder that strategics are still willing to buy differentiated platforms that can slot cleanly into an existing commercial engine.

Endovascular Today

2. 💰 Gilead to acquire Tubulis in up to $5 billion deal to strengthen oncology pipeline

The size of the deal stands out, but so does the thesis: targeted delivery platforms still command premium strategic value when they bring credible clinical assets with them. Even for device operators, it is a useful signal that platform-plus-pipeline stories continue to attract real buyer urgency.

MedTech World

3. 🎯 86% of Medtech Teams Have Claims Their Evidence Can’t Back Up

In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.

We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.

If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, this is the window to find out. We’re accepting a small number of medtech teams now.

→ See if you qualify

4. 🔬 Monteris Medical Secures $28 Million in Growth Equity to Accelerate Revenue and Innovation in Minimally Invasive Neurosurgery

Monteris is raising growth capital to expand its U.S. commercial footprint, push technology development, and deepen clinical research around NeuroBlate. That combination matters: investors are still backing companies that can pair procedural differentiation with evidence generation and a clear path to broader adoption across health systems.

PR Newswire

5. 🤖 Luminai Raises $38 million Series B to Scale Intelligence Across Health System Operations

AI stories are everywhere, but Luminai’s angle is operational infrastructure rather than headline-grabbing automation theater. That makes this one worth watching: health systems are increasingly buying tools that promise workflow lift, measurable labor leverage, and cleaner execution in the back half of care delivery.

PR Newswire

6. 😴 ProSomnus gets FDA nod for latest sleep apnea therapy device

ProSomnus’ FDA clearance for RPMO₂ adds physiologic monitoring to oral appliance therapy, pushing sleep apnea treatment toward a more data-rich, feedback-driven model. Strategically, that is the interesting part: devices that do not just treat, but also generate monitoring data, tend to create stronger clinical and commercial positioning.

MassDevice

7. 🏥 Dimer Health Raises $13.5 Million | Thesis Care Announces $45 Million Series A

Both raises point at the same pressure point: health systems still need capacity, especially in moments where labor-intensive clinical work creates bottlenecks. Dimer’s post-discharge model and Thesis Care’s AI-supported clinical teams both reflect where buyers are spending now — on tools that promise operational relief without pretending clinicians are optional.

Healthcare IT Today

8. 🧬 Miracell Secures U.S. FDA Clearance for SMART M-CELL, Advancing Regenerative Therapies

Miracell’s 510(k) clearance adds another data point to the broader regenerative medicine buildout, especially around systems that aim to preserve cell viability while making extraction and concentration more usable in practice. It is still an earlier signal than some of the stories above, but it is a category worth tracking as procedural regenerative applications continue to mature.

BioPharma APAC

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial

For years, Watchman has occupied a clear place in the atrial fibrillation treatment map. It was the device you talked about when blood thinners stopped looking like a clean long-term answer.

CHAMPION-AF suggests Boston Scientific wants to redraw that map.

The headline result was strong enough to invite that ambition. In data presented at ACC.26 and simultaneously published in the New England Journal of Medicine, Watchman FLX met non-inferiority against NOACs on a composite primary efficacy endpoint of cardiovascular death, stroke, and systemic embolism. On the primary safety endpoint — non-procedural bleeding — the device didn’t just clear the bar. It showed statistical superiority, with a combined rate of major and clinically relevant non-major bleeding of 15.1% versus 21.8% in the NOAC arm. Boston Scientific has said it plans to use the trial to pursue both an expanded label and a revised Medicare national coverage decision.

One other thing worth noting before getting to the market argument: this is structurally different from prior Watchman evidence. PROTECT-AF and PREVAIL compared the device against warfarin — a therapy the field had largely moved past. CHAMPION-AF is the first large randomized trial to put Watchman head-to-head against DOACs, in patients who were actually eligible for anticoagulation. That distinction matters for how much weight the result can carry.

On one level, this is a familiar medtech story: generate the evidence, widen the indication, grow the franchise.

But this one matters because it is really a story about where stroke prevention happens.

Drug-based prevention has always had one enormous advantage over device-based prevention: it fits the default logic of care. A prescription is easy to write, easy to scale, and easy to understand. A structural heart procedure is none of those things. It asks for specialist judgment, lab capacity, procedural confidence, and a reimbursement structure that makes the extra work worthwhile.

So when Boston Scientific pushes Watchman deeper into the market, it is not just asking whether the device works. It is asking whether the care pathway itself is ready to change.

That is a much bigger question.

Left atrial appendage closure is no longer an isolated niche. Boston Scientific has described Watchman as a major growth platform, and its broader structural heart messaging makes clear that the company sees this market as something to build outward, not simply defend.

The commercial logic is easy to see. If physicians and payers become more comfortable treating Watchman as an earlier option rather than a later fallback, Boston Scientific does not just sell more devices. It expands the category’s clinical perimeter.

That is where the trial starts to feel more consequential than a typical positive readout.

Because the real contest here is not device versus drug. It is routine versus exception.

Watchman has historically benefited from a simple narrative: some patients need an alternative to chronic anticoagulation. What Boston Scientific is now testing is whether that narrative can be broadened. Can an implant move from being the answer for selected patients to being a reasonable first conversation for many more of them?

That is a tougher leap than it sounds.

Physicians do not change habits because a company wants a larger market. They change habits when the evidence is persuasive, the workflow becomes manageable, and the economic logic stops fighting the clinical one. Even then, adoption tends to move unevenly. Leading centers go first. Everyone else waits to see whether the enthusiasm becomes routine practice.

And CHAMPION-AF, for all its upside, still leaves some room for hesitation. Ischemic stroke was numerically higher in the device arm — 3.2% versus 2.2% — a difference that was not statistically significant on a secondary endpoint, but one that the trial’s own investigators flagged as requiring longitudinal follow-up. The five-year data, not yet available, will be the more decisive read on that signal.

The trial also sits in a more complicated evidentiary landscape than its top-line results suggest. CLOSURE-AF, presented at AHA 2025, found that left atrial appendage occlusion failed to meet noninferiority against standard care in patients at high combined risk of stroke and bleeding — a population where the procedure has been most widely used. The NEJM editorial accompanying CHAMPION-AF cited that result directly, and several prominent cardiologists argued the negative trial raises the burden of proof for any new LAAC evidence. Boston Scientific’s data are more favorable, and in a meaningfully different patient population, but the field is not reading CHAMPION-AF in a vacuum.

None of that negates the result. But it does keep the conversation open.

Which is probably why this story performed so well in the first place.

It is not just a good-news clinical trial story. It is a market-shaping argument disguised as one.

Readers can feel the stakes immediately. If Watchman stays where it is today, Boston Scientific still has an important franchise. If the company succeeds in shifting physician behavior and payer confidence, then left atrial appendage closure begins to look less like a carveout and more like a reordering of the atrial fibrillation treatment stack.

That is the difference between a product win and a category win.

And this week, the market seems to have recognized that difference.

The question now is not whether Watchman generated positive data. It is whether Boston Scientific has finally assembled enough evidence to make a procedure compete with the default convenience of a pill.

SPONSORED

Your Commercial Story Will Get Tested.
The Question Is When.

You’ll spend years getting to clearance. You’ll spend weeks preparing the deck. Most teams never spend a day finding out whether their commercial story actually holds up from the outside.

That’s the gap the CLiF Pioneer Cohort closes — before a fundraise, a launch, or a partnership conversation where it’s too late to fix it.

Ten seats. Two rounds. Half the rate.

Claim your seat →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 💰 Whoop raises $575M, eyes IPO as health platform scales

Whoop’s latest raise and IPO ambitions signal continued investor appetite for consumer-driven health platforms—especially those positioning as longitudinal data engines rather than single-use devices. The question now: how far can wearables stretch into clinical relevance?

The Next Web

2. 🔐 Stryker contains cyberattack, begins system restoration

Stryker confirmed a cyberattack impacting systems, now contained as recovery begins. The bigger signal: medtech remains highly exposed to operational disruption—and cybersecurity is quickly becoming a board-level risk, not just an IT issue.

Cybersecurity Dive

3. 🎯 86% of Medtech Companies Have a Hidden Deal Risk

In our Q1 client study, we discovered that 86% of companies had claims that outpaced their evidence—enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters. We recently caught this in a company preparing for a $25M Series A!

RŌG Health exists for this exact moment: to surface where your story doesn’t hold up before it costs you.

We’re working with a small group of medtech teams going through this now.
→ Learn more

Sponsored

4. 🫀 J&J’s Impella shows no patient benefit in major trials

New trial data found no meaningful patient benefit for Impella heart pumps, raising serious questions about clinical value versus widespread adoption. Expect ripple effects across cardiac device positioning and hospital purchasing scrutiny.

MedTech Dive

5. 🩺 Boston Scientific’s Watchman shows reduced reliance on blood thinners

New data suggests Watchman may help patients avoid long-term blood thinner use, reinforcing its value proposition in atrial fibrillation care. It’s another step toward device-led alternatives to chronic drug therapy.

Fierce Biotech

6. 🧠 Philips wins FDA clearance for next-gen imaging system

Philips secured FDA clearance for a new imaging platform, continuing its push to modernize diagnostic workflows. Imaging remains a battleground for incremental innovation with outsized operational impact.

Yahoo Finance

7. ⚡ GE Healthcare’s Photonova Spectra clearance signals imaging push

GE Healthcare’s latest FDA clearance adds to its imaging portfolio, signaling continued investment in advanced diagnostics. The broader play: tighter integration of imaging into data-driven care pathways.

Simply Wall St

8. 🧪 eMed raises $200M at $2B+ valuation

eMed’s $200M raise highlights sustained investor interest in decentralized diagnostics and digital care models. The question is whether these platforms can convert pandemic-era momentum into durable infrastructure.

PR Newswire

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.